


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application. In amendments to the claims, additions are represented by underlining and deletions are represented by ~~striketrough~~ or, in cases of five characters or fewer, by ~~[[double brackets]]~~.

1. (Currently Amended) A method for inhibiting anchorage dependent cancer cell proliferation comprising administering a NF-κB inhibitor to a subject, wherein the NF-κB inhibitor causes an NF-κB inhibition and has the structure




wherein R², R³, and R⁴ are, independently, hydrogen, alkyl, halogenated alkyl, alkenyl, alkynyl, aralkyl, or substituted or unsubstituted aromatic, wherein the compound is the E- or Z-isomer, and wherein the subject has had a tumor resected ~~has cancer cells which are proliferating, wherein the cancer cells are not myeloma cells.~~


- 2-7. (Canceled)
8. (Previously Presented) The method of claim 1, wherein the cancer is an abdominal cancer, hepatic cancer, peritoneal cancer, parietal cancer, rectal cancer, stomach cancer, or colon cancer.
9. (Previously Presented) The method of claim 1, wherein the cancer cells utilize NF-κB for mitogenesis.
10. (Previously Presented) The method of claim 1, wherein the cancer cells utilize NF-κB for readhesion.

11. (Previously Presented) The method of claim 1, wherein the cancer cell comprises an APC mutation.
12. (Previously Presented) The method of claim 1, wherein the cancer cell does not contain an activating mutation on β -catenin.
13. (Previously Presented) The method of claim 1, wherein the cancer cell expresses the COX2 gene.
14. (Previously Presented) The method of claim 13, wherein the cancer cell overexpresses the COX2 gene.
15. (Previously Presented) The method of claim 1, wherein the cancer cell does not express the COX2 gene.
16. (Withdrawn) The method of claim 1, wherein the cancer cell is related to a cancer cell line.
17. (Withdrawn) The method of claim 16, wherein the cancer cell line is a DLD-1 cell line or a HT-29 cell line.
18. (Previously Presented) The method of claim 1, wherein the cancer cells are colon cancer cells.
19. (Withdrawn) The method of claim 1, wherein the cancer cells are rectal cancer cells.
20. (Withdrawn) The method of claim 1, wherein the cancer cells are not adenocarcinoma cells.
21. (Original) The method of claim 1, wherein inhibiting cancer cell proliferation is independent of TNF α activated apoptosis.
- 22-25. (Canceled)
26. (Previously Presented) The method of claim 1, wherein the NF- κ B inhibitor causes a decrease in the expression of anti-apoptotic proteins.

27. (Previously Presented) The method of claim 1, wherein the NF- κ B inhibitor inhibits IkB phosphorylation.
28. (Previously Presented) The method of claim 1, wherein the NF- κ B inhibitor inhibits TNF α induced NF- κ B activation.
- 29-36. (Canceled)
37. (Currently Amended) The method of ~~claim 36~~ claim 1, wherein R³ and R⁴ are hydrogen.
38. (Currently Amended) The method of ~~claim 36~~ claim 1, wherein R² is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tertiary butyl, substituted or unsubstituted phenyl, or benzyl.
39. (Currently Amended) The method of ~~claim 36~~ claim 1, wherein R² is a phenyl group having at least one alkyl group.
40. (Currently Amended) The method of ~~claim 36~~ claim 1, wherein the compound is the E-isomer.
41. (Withdrawn) The method of claim 1, wherein the NF- κ B inhibitor has the structure



42. (Previously Presented) The method of claim 1, wherein the NF- κ B inhibitor has the structure



43-52. (Canceled)

- 53. (Previously Presented) The method of claim 1, wherein the NF-κB inhibitor directly inhibits NF-κB.
- 54. (Previously Presented) The method of claim 1, wherein the NF-κB inhibitor indirectly inhibits NF-κB.
- 55. (Previously Presented) The method of 54, wherein the NF-κB inhibitor inhibits expression of NF-κB.
- 56. (Previously Presented) The method of 54, wherein the NF-κB inhibitor inhibits translation of NF-κB.
- 57. (Previously Presented) The method of claim 1, wherein the NF-κB inhibitor inhibits NF-κB transport into the nucleus.

58-64. (Canceled)

- 65. (Currently Amended) The method of ~~claim 64~~ claim 1, wherein the NF-κB inhibitor is administered prior to the resection.
- 66. (Currently Amended) The method of ~~claim 64~~ claim 1, wherein the NF-κB inhibitor is administered after the resection.
- 67. (Currently Amended) The method of ~~claim 64~~ claim 1, wherein the NF-κB inhibitor is administered within 10 days of the resection.

68. (Currently Amended) The method of ~~claim 64~~ claim 1, wherein the NF- κ B inhibitor is administered within 5 days of the resection.
69. (Currently Amended) The method of ~~claim 64~~ claim 1, wherein the NF- κ B inhibitor is administered within 1 days of the resection.
70. (Currently Amended) The method of ~~claim 64~~ claim 1, wherein the NF- κ B inhibitor is administered within 10 hours of the resection.
71. (Currently Amended) The method of ~~claim 64~~ claim 1, wherein the NF- κ B inhibitor is administered within 1 hour of the resection.
72. (Currently Amended) The method of ~~claim 64~~ claim 1, wherein the NF- κ B inhibitor is administered within 0.5 hours of the resection.